Telo Genomics Corp Cash Flow-to-Debt Ratio
Telo Genomics Corp cash flow-to-debt ratio. Telo Genomics Corp (TELO) has a Cash Flow-to-Debt Ratio of -0.47x as of September 2025, meaning its operating cash flow of CA$-300.71K could theoretically repay 0% of its total liabilities (CA$633.60K) in one year. Check Telo Genomics Corp cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Telo Genomics Corp (2013–2025)
Cash flow-to-debt ratio of Telo Genomics Corp from 2013 to 2025. Historical debt coverage capacity for Telo Genomics Corp across 13 annual periods. Check TELO total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Telo Genomics Corp Cash Flow-to-Debt Ratio by Year (2013–2025)
Telo Genomics Corp cash flow-to-debt ratio by year from 2013 to 2025. Year-by-year debt coverage analysis for Telo Genomics Corp. For the full cash flow conversion analysis, see TELO operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.88x | CA$-2.33 Million | CA$396.32K | ▲ +10.3% |
| 2024 | -6.55x | CA$-2.46 Million | CA$375.59K | ▲ +22.1% |
| 2023 | -8.40x | CA$-2.63 Million | CA$312.87K | ▼ -7.7% |
| 2022 | -7.80x | CA$-1.79 Million | CA$230.07K | ▼ -8.5% |
| 2021 | -7.19x | CA$-1.10 Million | CA$153.66K | ▼ -152.6% |
| 2020 | -2.85x | CA$-1.12 Million | CA$393.42K | ▼ -1035.0% |
| 2019 | -0.25x | CA$-327.84K | CA$1.31 Million | ▲ +94.2% |
| 2018 | -4.31x | CA$-3.21 Million | CA$743.53K | ▲ +51.6% |
| 2017 | -8.91x | CA$-7.90 Million | CA$886.25K | ▼ -295.2% |
| 2016 | -2.26x | CA$-78.65K | CA$34.87K | ▲ +65.6% |
| 2015 | -6.55x | CA$-106.77K | CA$16.30K | ▼ -207.6% |
| 2014 | -2.13x | CA$-35.47K | CA$16.66K | ▲ +56.5% |
| 2013 | -4.90x | CA$-66.68K | CA$13.61K | — |